Abstract Number: 359 • 2014 ACR/ARHP Annual Meeting
14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, there are auto-antibodies (AAb) to…Abstract Number: 378 • 2014 ACR/ARHP Annual Meeting
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate
Background/Purpose The prediction of treatment outcomes based on early response could guide treatment decisions in patients (pts) with rheumatoid arthritis (RA). The objective was to…Abstract Number: 377 • 2014 ACR/ARHP Annual Meeting
Fatigue Fluctuates Substantially over Time in Rheumatoid Arthritis Patients Despite Stable Disease Activity during Treatment with Biological Agents
Background/Purpose Fatigue (FTG) is a symptom commonly reported by patients with rheumatoid arthritis (RA). Little is known about its nature and etiology. The number of…Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…Abstract Number: 374 • 2014 ACR/ARHP Annual Meeting
IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study
Background/Purpose Clinical remission is achievable for patients with early rheumatoid arthritis (ERA). Identification of predictors for response of treatment may provide risk estimation and help…Abstract Number: 373 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis
Background/Purpose Rheumatoid arthritis (RA) is associated with accelerated coronary atherogenesis, myocardial infarction, and mortality. We previously reported a higher prevalence, severity, and different composition of…Abstract Number: 372 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain
Background/Purpose: To assess the sensitivity, specificity, and predictive values of rheumatoid factor (RF) as a test for rheumatoid arthritis (RA) in primary care, and to…Abstract Number: 371 • 2014 ACR/ARHP Annual Meeting
The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) on Outcomes in Early Rheumatoid Arthritis: From the Canadian Early Arthritis Cohort
Background/Purpose: The impact of missing ACPA in early inflammatory arthritis patients was studied to determine if failure to perform ACPA testing could cause a care…Abstract Number: 358 • 2014 ACR/ARHP Annual Meeting
Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study
Background/Purpose Female sex and older age are known risk factors for rheumatoid arthritis (RA). The disease is however heterogeneous, and a common division occurs between…Abstract Number: 357 • 2014 ACR/ARHP Annual Meeting
Development and Validation of a Diagnostic Bead-Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect “Seronegative” Rheumatoid Arthritis
Background/Purpose: Autoantibodies (auto-Ab) against citrullinated peptides (ACPA) and rheumatoid factor (RF) are important biomarkers in the diagnostic process of rheumatoid arthritis (RA). However, RF or…Abstract Number: 356 • 2014 ACR/ARHP Annual Meeting
The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Background/Purpose: The Rheumatoid arthritis impact of disease (RAID) score is a relatively new patient-derived composite score assessing the seven most important domains of the impact…Abstract Number: 355 • 2014 ACR/ARHP Annual Meeting
Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Magnetic Resonance Imaging
Background/Purpose Patients with rheumatoid arthritis (RA) experience an excess risk of congestive heart failure (CHF), but effects of disease-modifying anti-rheumatic drugs (DMARDs) on cardiac structure…Abstract Number: 354 • 2014 ACR/ARHP Annual Meeting
Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG-PET/CT Scan
Background/Purpose : Patients with rheumatoid arthritis (RA) have an elevated risk of developing cardiovascular disease (CVD). Like active RA, atherosclerosis is an inflammatory process. There…Abstract Number: 353 • 2014 ACR/ARHP Annual Meeting
Sensitivity of Unique Multidimensional Health Assessment Questionnaire Items Compared to Items on Both the HAQ and MDHAQ in Patients with RA and SLE
Background/Purpose: Patients with rheumatic diseases have significantly better clinical status in recent years than in previous decades, including rheumatoid arthritis (RA)1 and systemic lupus erythematosus…
ACR Meeting Abstracts